Literature DB >> 31335989

Prevalence and correlates of diabetes distress, perceived stress and depressive symptoms among adults with early-onset Type 2 diabetes: cross-sectional survey results from the Danish DD2 study.

A Bo1,2, F Pouwer3,4,5, L Juul6, S K Nicolaisen7, H T Maindal1,8.   

Abstract

AIMS: To establish the prevalence of diabetes distress, perceived stress and depressive symptoms among adults with early-onset Type 2 diabetes, and to examine their association with socio-demographic and clinical characteristics.
METHODS: A cross-sectional survey was performed among individuals with Type 2 diabetes aged 20-45 years who were included in the Danish nationwide Danish Center for Strategic Research in Type 2 Diabetes cohort between 2010 and 2016. The survey assessed diabetes distress (20-item Problem Areas in Diabetes Scale), perceived stress (10-item Perceived Stress Scale) and depressive symptoms (10-item short form of the Center for Epidemiological Studies Depression Scale Revised), as well as socio-demographic characteristics. Clinical data were collected from national health registers.
RESULTS: In total, 216/460 (47%) individuals (48% women) with Type 2 diabetes completed the survey. The median (IQR) age was 42 (38-44) years and the diabetes duration was 5 (3-7) years. In total, 24% of respondents reported high diabetes distress (Problem Areas in Diabetes Scale ≥ 40), 46% reported high perceived stress (Perceived Stress Scale ≥ 18) and 41% reported elevated symptoms of depression (Center for Epidemiological Studies Depression Scale Revised ≥ 10). The prevalence of emotional problems was higher among women than men. Diabetes distress was higher among those prescribed non-insulin glucose-lowering drugs (vs. no glucose-lowering drugs), but was not associated with other clinical or socio-demographic characteristics. High perceived stress was associated with being unemployed and using antidepressant medication, and elevated depressive symptoms were associated with low education level, unemployment, living alone, having a psychiatric disorder and using antidepressant medication.
CONCLUSION: We found a high prevalence of emotional problems among adults with early-onset Type 2 diabetes in Denmark. Health care for this group should focus on both physical health and psychosocial circumstances and should also address general as well as diabetes-specific emotional problems.
© 2019 Diabetes UK.

Entities:  

Year:  2019        PMID: 31335989     DOI: 10.1111/dme.14087

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  5 in total

Review 1.  Developing and Evaluating Behaviour Change Interventions for People with Younger-Onset Type 2 Diabetes: Lessons and Recommendations from Existing Programmes.

Authors:  Amelia J Lake; Anne Bo; Michelle Hadjiconstantinou
Journal:  Curr Diab Rep       Date:  2021-12-13       Impact factor: 4.810

2.  Empowerment among adult patients with type 2 diabetes: age differentials in relation to person-centred primary care, community resources, social support and other life-contextual circumstances.

Authors:  Nina Simonsen; Anne M Koponen; Sakari Suominen
Journal:  BMC Public Health       Date:  2021-05-01       Impact factor: 4.135

3.  The Association Between General Self-Efficacy and Depressive Symptoms in People with Type 2 Diabetes Mellitus: The Mediating Role of Coping Styles Preference.

Authors:  Qingting Li; Yao Chen; Maritta Välimäki; Qing Long; Jundi Yang; Jia Guo
Journal:  Psychol Res Behav Manag       Date:  2022-09-08

4.  Diabetes Distress in Young Adults with Type 2 Diabetes: A Cross-Sectional Survey in China.

Authors:  Yanfen Hu; Lingxia Li; Jun Zhang
Journal:  J Diabetes Res       Date:  2020-06-18       Impact factor: 4.011

5.  Psychological Distress and All-Cause, Cardiovascular Disease, Cancer Mortality Among Adults with and without Diabetes.

Authors:  Wentao Huang; Dagfinn Aune; Gerson Ferrari; Lei Zhang; Yutao Lan; Jing Nie; Xiong Chen; Dali Xu; Yafeng Wang; Leandro F M Rezende
Journal:  Clin Epidemiol       Date:  2021-07-13       Impact factor: 4.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.